Menu
HeartFlow, Inc. to Announce New Data on Diagnosing and Managing Coronary Artery Disease at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting
MOUNTAIN VIEW, Calif. – July 24, 2023 — HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.
“The data being presented at SCCT are the latest findings in a robust body of evidence that show HeartFlow technologies help clinicians further improve diagnostic accuracy and clinical decision-making to ensure the right patients are getting the right care at the right time,” said Campbell Rogers, Chief Medical Officer of HeartFlow. “Our continued investment in research underscores not only our culture of innovation but also our unwavering commitment to quality in order to develop best-in-class products to support physicians and the patients they treat.”
Title: “Primary Results Of The REVEALPLAQUE Study: A Prospective Quantitative Assessment Of AI-based CCTA Plaque Volume Compared With IVUS”
Date and Time: July 28, 9:30-10:15 AM EDT (Session 8)
Speaker: Jagat Narula, M.D. UTHealth Houston
Location: Exhibit Hall (Hynes Convention Center)
Title: “Utility Of AI Plaque Quantification: Results Of The Decisions For Treating Coronary Disease Are Changed In Patients Evaluated With Quantified Plaque Analysis (DECODE) Study”
Date and Time: July 28, 9:30-10:15 AM EDT (Session 8)
Speaker: Sarah Rinehart, M.D. Charleston Area Medical Center
Location: Exhibit Hall (Hynes Convention Center)
Title: “A Study To Measure the Ability of the RoadMap Analysis to Support CCTA Reading Efficiency, Confidence, and Reproducibility (SMART-CT)”
Date and Time: July 29, 9:40-10:30 AM EDT (Session 10)
Speaker: Michael Morris, M.D., Banner Health
Location: Exhibit Hall (Hynes Convention Center)
Title: Comparison of AI-based CCTA Interpretation and QCA for Coronary Stenosis Evaluation “(RoadMap Accuracy)”
Date and Time: July 29, 9:40-10:30 AM EDT (Session 10)
Speaker: James Dundas, M.D., University of British Columbia and St Paul’s Hospital, Vancouver, British Columbia, Canada
Location: Exhibit Hall (Hynes Convention Center)
Heartflow is also hosting a symposium on Friday, July 28, 7:00-7:50 AM ET in Room 312. Featured speakers include Jonathon Leipsic, M.D., FSCCT, former president of SCCT; Jagat Narula, M.D., PhD, MACC, Executive Vice President and Chief Academic Officer at UTHealth Houston; Wesley O’Neal, M.D., MPH, FACC, Director, Cardiac CT and Nuclear Cardiology at Cone Health Heart & Vascular Center and Sarah Rinehart, M.D., FACC, FSCCT, Director of Cardiac Imaging, Director of Cardiology Fellowship at Charleston Area Medical Center. Company representatives will also be available during the conference at Booth 207.
###
HeartFlow is the global leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced AI technology. Headquartered in Mountain View, California, our technology has been published in more than 500 peer-reviewed publications that showcase the value of anatomy, physiology, and plaque. We began our journey to improve coronary artery disease (CAD) diagnosis with FFRCT and have now expanded our product portfolio to include anatomic stenosis and plaque information. To date, clinicians have used our technology for over 200,000 patients to aid in the diagnosis of heart disease. For more information, visit www.heartflow.com and connect on Twitter and LinkedIn.
Linly Ku
HeartFlow
media@heartflow.com
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.